<DOC>
	<DOCNO>NCT00000646</DOCNO>
	<brief_summary>To determine whether pentoxifylline lower tumor necrosis factor ( TNF ) level AIDS patient . Pentoxifylline decrease tumor necrosis factor ( TNF ) , therefore decrease TNF-intensified event cachexia , enhance HIV expression , inhibition zidovudine ( AZT ) activity .</brief_summary>
	<brief_title>Pentoxifylline ( Trental ) Modulator Tumor Necrosis Factor HIV Replication Patients With AIDS</brief_title>
	<detailed_description>Pentoxifylline decrease tumor necrosis factor ( TNF ) , therefore decrease TNF-intensified event cachexia , enhance HIV expression , inhibition zidovudine ( AZT ) activity . Twenty-seven AIDS patient elevate TNF le 300 CD4 cell give pentoxifylline 3 time day 8 week . If significant change see virologic , immunologic , related measure , 27 additional patient give high dose pentoxifylline 3 time day eight week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) , combination thereof , current dosage 8 week study treatment . Prophylaxis ( e.g. , aerosolized pentamidine , trimethoprim / sulfamethoxazole ( TMP / SMX ) , dapsone Pneumocystis carinii pneumonia ( PCP ) CD4 cell count &lt; 200 cells/mm3 Allowed : Concurrent maintenance therapy opportunistic infection . Prior Medication : Required : Zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) , combination thereof , least 2 month . Patients must follow : Diagnosis AIDS . Documented HIV seropositivity . Ability give inform consent willingness comply visit schedule procedure . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Lymphoma visceral Kaposi 's sarcoma . Active peptic ulcer bleed disorder . Hemophilia . Known intolerance pentoxifylline , theophylline , caffeine . Concurrent Medication : Excluded : Warfarin heparin . Biological response modifier ( e.g. , erythropoietin , interferon , GCSF , GMCSF ) . Cytotoxic chemotherapy . Megestrol acetate . Corticosteroids . Concurrent Treatment : Excluded : Radiation therapy . Blood product transfusion . Patients follow exclude : Presence active opportunistic infection . Major surgery within 30 day study treatment . Prior Medication : Excluded : Biological response modifier ( include interferon , interleukin ) , corticosteroid , megestrol acetate within 14 day first ( screen ) TNF level . Erythropoietin dependency within 30 day study treatment . Prior Treatment : Excluded : Transfusion blood product dependency use within 30 day study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pentoxifylline</keyword>
	<keyword>Virus Replication</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Drug Synergism</keyword>
</DOC>